Secondary outcomes | Measuring method |
---|---|
1. Change in the number of drugs immediately after the encounter and 6 months later | Medication list at baseline and after 6 months |
2. Reason for a change, categorized in the 4 options of the algorithm, number of drugs in each category 12 months after applying the tool | Medication list of the changed medications after the intervention, with the reason for a change |
3. Discrepancy in the decision to quit, change or continue the drug between PCP and patient | Medication list after intervention with any suggestion from the PCP for a change; medication list after the intervention and after shared-decision-making |
4. Number of drugs for which the patient is suggesting a change | Medication lists at baseline, after 6 and 12 months |
5. Number of drugs the patient is taking not known to the PCP | Medication lists at baseline, after 6 and 12 months |
6. Time consumption of the intervention | Measurement of the time through the practice nurse and the PCP |
7. Disease-specific variables to evaluate the course of the disease(s) for which the patient is being treated | Symptom scores and measurements of biometric analysis (e.g. blood pressure monitoring, serum glucose) and VAS scales (e.g. pain). Event rates (hospitalization, death) and unexpected adverse event rates |
8. Number of drugs readopted due to an unfavorable course of the disease(s) (readoption rate) | Medication lists at baseline, after 6 and 12 months |
9. Quality of life (QoL) | Patient rating on a 5-point Likert scale |
EQ-5D-3 L at baseline, after 6 and 12 months | |
10. Barriers perceived by patients and PCPs against the approach/algorithm | Phone interview with the patients 13 months after intervention |
11. Number of drugs which have been started | Medication lists at baseline, after 6 and 12 months |